vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Xenia Hotels & Resorts, Inc. (XHR). Click either name above to swap in a different company.
Xenia Hotels & Resorts, Inc. is the larger business by last-quarter revenue ($295.4M vs $191.2M, roughly 1.5× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 2.2%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 4.0%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Xenia Hotels & Resorts, Inc. is a real estate investment trust that invests in hotels. As of December 31, 2024, it owned 31 hotels comprising 9,408 rooms.
AXSM vs XHR — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $295.4M |
| Net Profit | — | $19.8M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | 14.1% |
| Net Margin | — | 6.7% |
| Revenue YoY | 57.4% | 2.2% |
| Net Profit YoY | — | 26.9% |
| EPS (diluted) | — | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $295.4M | ||
| Q4 25 | $196.0M | $265.6M | ||
| Q3 25 | $171.0M | $236.4M | ||
| Q2 25 | $150.0M | $287.6M | ||
| Q1 25 | $121.5M | $288.9M | ||
| Q4 24 | $118.8M | $261.8M | ||
| Q3 24 | $104.8M | $236.8M | ||
| Q2 24 | $87.2M | $272.9M |
| Q1 26 | — | $19.8M | ||
| Q4 25 | $-28.6M | $6.1M | ||
| Q3 25 | $-47.2M | $-13.7M | ||
| Q2 25 | $-48.0M | $55.2M | ||
| Q1 25 | $-59.4M | $15.6M | ||
| Q4 24 | $-74.9M | $-638.0K | ||
| Q3 24 | $-64.6M | $-7.1M | ||
| Q2 24 | $-79.3M | $15.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 30.4% | ||
| Q3 25 | — | 25.1% | ||
| Q2 25 | — | 33.6% | ||
| Q1 25 | — | 32.3% | ||
| Q4 24 | — | 29.0% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 31.9% |
| Q1 26 | -33.1% | 14.1% | ||
| Q4 25 | -13.8% | 10.1% | ||
| Q3 25 | -27.0% | 2.0% | ||
| Q2 25 | -24.5% | 14.0% | ||
| Q1 25 | -46.9% | 12.4% | ||
| Q4 24 | -61.1% | 8.2% | ||
| Q3 24 | -59.8% | 3.2% | ||
| Q2 24 | -89.5% | 11.1% |
| Q1 26 | — | 6.7% | ||
| Q4 25 | -14.6% | 2.3% | ||
| Q3 25 | -27.6% | -5.8% | ||
| Q2 25 | -32.0% | 19.2% | ||
| Q1 25 | -48.9% | 5.4% | ||
| Q4 24 | -63.1% | -0.2% | ||
| Q3 24 | -61.7% | -3.0% | ||
| Q2 24 | -91.0% | 5.6% |
| Q1 26 | — | $0.21 | ||
| Q4 25 | $-0.55 | $0.07 | ||
| Q3 25 | $-0.94 | $-0.14 | ||
| Q2 25 | $-0.97 | $0.56 | ||
| Q1 25 | $-1.22 | $0.15 | ||
| Q4 24 | $-1.54 | $-0.01 | ||
| Q3 24 | $-1.34 | $-0.07 | ||
| Q2 24 | $-1.67 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $101.1M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $1.2B |
| Total Assets | $713.6M | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | $101.1M | ||
| Q4 25 | $322.9M | $140.4M | ||
| Q3 25 | $325.3M | $188.2M | ||
| Q2 25 | $303.0M | $172.6M | ||
| Q1 25 | $300.9M | $112.6M | ||
| Q4 24 | $315.4M | $78.2M | ||
| Q3 24 | $327.3M | $161.5M | ||
| Q2 24 | $315.7M | $143.6M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $88.3M | $1.1B | ||
| Q3 25 | $73.7M | $1.2B | ||
| Q2 25 | $73.1M | $1.2B | ||
| Q1 25 | $53.2M | $1.2B | ||
| Q4 24 | $57.0M | $1.2B | ||
| Q3 24 | $92.9M | $1.3B | ||
| Q2 24 | $102.9M | $1.3B |
| Q1 26 | $713.6M | $2.8B | ||
| Q4 25 | $689.8M | $2.8B | ||
| Q3 25 | $669.3M | $2.9B | ||
| Q2 25 | $639.8M | $2.9B | ||
| Q1 25 | $596.7M | $2.9B | ||
| Q4 24 | $568.5M | $2.8B | ||
| Q3 24 | $561.5M | $2.9B | ||
| Q2 24 | $548.2M | $2.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.25× | ||
| Q3 25 | — | 1.21× | ||
| Q2 25 | — | 1.17× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.11× | ||
| Q2 24 | — | 1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
XHR
| Rooms revenues | $164.4M | 56% |
| Food and beverage revenues | $105.0M | 36% |
| Other revenues | $26.0M | 9% |
